Markets:

Overview

News

Currencies

International

Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.545 +0.075 (+5.10%)

Streaming Delayed Price Updated: 3:38 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗

Today 13:09 EST

Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.

Via Benzinga

The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance

December 04, 2025

Washington D.C. – December 4, 2025 – A persistent and increasingly vocal debate continues to plague the halls of Congress, centering on allegations that elected officials are leveraging their unique...

Via MarketMinute

Topics Bonds ETFs World Trade

Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress ↗

November 06, 2025

Allogene Therapeutics beat Q3 2025 earnings estimates with a narrower loss and reaffirmed its cash runway into 2027. The biotech also reported progress on its allogeneic CAR T pipeline.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares...

Via MarketMinute

Topics Initial Public Offering Regulatory Compliance Workforce

This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

October 10, 2025

Via Benzinga

Allogene Q2 Cash Tops $300 Million ↗

August 13, 2025

Via The Motley Fool

Allogene Narrows Loss in Fiscal Q2 ↗

August 13, 2025

Via The Motley Fool

Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly ↗

August 13, 2025

Allogene Therapeutics reported a Q2 2025 net loss of $0.23 per share, beating estimates, with revenue at $0. Shares rose 1% post-earnings as investors focused on cost discipline and clinical progress.

Via Chartmill

A Look at Allogene Therapeutics's Upcoming Earnings Report ↗

August 12, 2025

Via Benzinga

Allogene Therapeutics's Earnings Outlook ↗

May 12, 2025

Via Benzinga

A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics ↗

August 08, 2024

Via Benzinga

Analyst Ratings For Allogene Therapeutics ↗

May 31, 2024

Via Benzinga

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday ↗

August 04, 2025

Via Benzinga

Allogene Resets Clinical Course After Patient Death In Lymphoma Study ↗

August 01, 2025

Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating its clinical approach.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise ↗

February 23, 2025

Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy.

Via Stocktwits

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗

February 18, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Earnings Scheduled For March 13, 2025 ↗

March 13, 2025

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

February 18, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Friday's session: top gainers and losers ↗

February 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

What's going on in today's session ↗

February 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Friday's session: gap up and gap down stocks ↗

February 14, 2025

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

7 Biotech Stocks to Buy for Their Game-Changing Potential ↗

August 08, 2024

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Via InvestorPlace

Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges ↗

July 19, 2024

CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune...

Via Benzinga

If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names ↗

May 28, 2024

Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence.

Via InvestorPlace

Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 21, 2024

Via Benzinga

Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

May 21, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.